Global Viral Vector and Plasmid DNA Manufacturing market is valued at USD 697.16 Million in 2022 and is projected to attain a value of USD 2285.58 Million by 2030 at a CAGR of 16.00% during the forecast period, 2022–2028. The need for viral vector-based vaccinations for infectious illnesses is growing in tandem with the current shift in the treatment paradigm of various life-threatening diseases through sophisticated therapeutics. As a result, more Viral Vector and Plasmid DNA Manufacturing are being used in the R&D of new medicines, pushing the market for Viral Vector and Plasmid DNA Manufacturing manufacturing.
In addition, the COVID-19 epidemic has offered profitable prospects for market participants. For example, in December 2020 and February 2021, multinational pharmaceutical companies such as AstraZeneca and Janssen Pharmaceuticals developed COVID-19 viral vector-based vaccines, respectively. Aside from these firms, a number of viral vector-based vaccines are now in development. As a result, demand for viral vectors has increased, resulting in increased revenue for viral vector manufacturers.
Viral Vector and Plasmid DNA Manufacturing Market Size, 2022 To 2030 (USD Million)
Rising R&D Funding and Growing Initiatives
The availability of effective viral vector gene therapies for rare diseases and cancers, ongoing research on viral vector gene therapies, and the recent approval of many viral vector gene treatments are propelling this industry forward. As a result of the growing need for advanced clinical therapies and the growing importance of an expanding discipline in medical science, the Viral Vector and Plasmid DNA Manufacturing market has developed dramatically. Adenoviruses, baculoviruses, herpes simplex viruses, and other viral vectors are increasingly being used in the development of new drugs and vaccines.
Report Coverage & Deliverables
- Real-Time Data Updates:
- Competitor Benchmarking
- Market Trends Heatmap
- Custom Research Queries
- Market Sentiment Analysis
- Demographic and Geographic Insights
Manufacturing challenges associated with large-scale vector production may limit the market's growth. Because of increased investments by healthcare stakeholders in delivering innovative care delivery models, sophisticated digital technology, and many other things, the global healthcare industry has seen an increase in the availability of technologically advanced healthcare equipment. This has aided in the development of a sophisticated health ecosystem around the world. The growing healthcare infrastructure will open up new prospects in the industry, increasing demand for Viral Vector and Plasmid DNA Manufacturing around the world. However, legal, technical, and ethical problems involved with gene therapy, as well as production capacity restrictions and manufacturing challenges associated with large-scale vector production, are important factors limiting market expansion.
The Global Viral Vector and Plasmid DNA Manufacturing Market has been segmented by Product Type (Plasmid DNA, Viral Vector, And Non-Viral Vector), By Application (Cancer, Genetic Disorder, Infectious Disease, And Other Applications). By Region, North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Below tree is interactive. You can click the nodes to get more information.
North America to Continue Dominating the Viral Vector and Plasmid DNA Manufacturing Market
North America, Europe, and Asia Pacific accounted for the greatest proportion of the Viral Vector and Plasmid DNA Manufacturing market in 2021. Factors such as the increase in the number of well-established Viral Vector and Plasmid DNA Manufacturing companies and research institutes in the United States and Canada, a large number of ongoing research studies, and the overall growth of the healthcare sector on a global scale are among the few factors expected to contribute to the market's growth. One of the primary causes leading to the growing demand for Viral Vector and Plasmid DNA Manufacturing techniques and technologies among academic and research organisations, as well as healthcare firms in North America, is increased R&D spending.
Fujifilm Diosynth Biotechnologies, Fujifilm Diosynth Biotechnologies (US), SIRION Biotech (Germany), Thermo Fisher Scientific (US), Merck KGaA Inc. (US), Cognate BioServices Inc. (Cobra Biologics) (US) are the major companies operating in Global Viral Vector and Plasmid DNA Manufacturing Market.
Viral Vector and Plasmid DNA Manufacturing market is segmented as follows:
By Product Type
- Plasmid DNA
- Viral Vector
- Non-viral Vector
- Genetic Disorder
- Infectious Disease
- Other Applications
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
|Regions & Countries Covered
- North America - (U.S., Canada, Mexico)
- Europe - (U.K., France, Germany, Italy, Spain, Rest Of Europe)
- Asia Pacific - (China, Japan, India, South Korea, South East Asia, Rest Of Asia Pacific)
- Latin America - (Brazil, Argentina, Rest Of Latin America)
- Middle East & Africa - (GCC Countries, South Africa, Rest Of Middle East & Africa)
- Fujifilm Diosynth Biotechnologies (US)
- SIRION Biotech (Germany)
- Thermo Fisher Scientific (US)
- Merck KGaA Inc. (US)
- Cognate BioServices Inc. (Cobra Biologics) (US) are the major companies operating in Global Viral Vector and Plasmid DNA Manufacturing Market.
|Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST
analysis, value chain analysis, regulatory landscape, technology landscape, patent analysis, market
attractiveness analysis by segments and North America, company market share analysis, and COVID-19
Pricing and purchase options
|Avail of customized purchase options to meet your exact research needs. Explore purchase options
Viral Vector and Plasmid DNA Manufacturing market is tabulated as follows: